Ipsen and Medicis Announce Acceptance of Reloxin(R) BLA in Aesthetics by FDA

PARIS & SCOTTSDALE, Ariz.--(BUSINESS WIRE)-- Regulatory News: Ipsen (Paris:IPN) and Medicis (NYSE: MRX) today announced that the Food and Drug Administration (“FDA”) has accepted the filing of Ipsen’s Biologics License Application (“BLA”) for Reloxin®, its botulinum toxin type A in aesthetic use (glabellar lines) in the United States. This acceptance signifies the start of the review process of the dossier.